Söndag 5 April | 10:55:12 Europe / Stockholm

Svenska | English

Biogen Inc.

Kalender

	Est. tid*
2027-02-09	N/A	Bokslutskommuniké 2026
2026-10-26	N/A	Kvartalsrapport 2026-Q3
2026-07-28	N/A	Kvartalsrapport 2026-Q2
2026-06-09	N/A	Årsstämma
2026-04-24	N/A	Kvartalsrapport 2026-Q1
2026-02-06	-	Bokslutskommuniké 2025
2025-10-30	-	Kvartalsrapport 2025-Q3
2025-07-31	-	Kvartalsrapport 2025-Q2
2025-06-17	-	Årsstämma
2025-05-01	-	Kvartalsrapport 2025-Q1
2025-02-12	-	Bokslutskommuniké 2024
2024-10-30	-	Kvartalsrapport 2024-Q3
2024-08-01	-	Kvartalsrapport 2024-Q2
2024-06-20	-	Årsstämma
2024-04-24	-	Kvartalsrapport 2024-Q1
2024-02-13	-	Bokslutskommuniké 2023
2023-10-24	-	Kvartalsrapport 2023-Q3
2023-07-25	-	Kvartalsrapport 2023-Q2
2023-06-26	-	Årsstämma
2023-04-25	-	Kvartalsrapport 2023-Q1
2023-02-15	-	Bokslutskommuniké 2022
2022-10-25	-	Kvartalsrapport 2022-Q3
2022-07-20	-	Kvartalsrapport 2022-Q2
2022-06-15	-	Årsstämma
2022-05-03	-	Kvartalsrapport 2022-Q1
2022-02-03	-	Bokslutskommuniké 2021
2021-10-20	-	Kvartalsrapport 2021-Q3
2021-07-22	-	Kvartalsrapport 2021-Q2
2021-06-02	-	Årsstämma
2021-04-22	-	Kvartalsrapport 2021-Q1
2021-02-03	-	Bokslutskommuniké 2020
2020-10-21	-	Kvartalsrapport 2020-Q3
2020-07-22	-	Kvartalsrapport 2020-Q2
2020-06-03	-	Årsstämma
2020-04-22	-	Kvartalsrapport 2020-Q1
2020-01-30	-	Bokslutskommuniké 2019
2019-10-22	-	Kvartalsrapport 2019-Q3
2019-07-23	-	Kvartalsrapport 2019-Q2
2019-06-19	-	Årsstämma
2019-04-24	-	Kvartalsrapport 2019-Q1

Beskrivning

Land	USA
Sektor	Hälsovård
Industri	Läkemedel & Handel

Biogen är ett läkemedelsbolag. Bolaget är fokuserade mot att erbjuda behandling av allvarliga och sällsynta sjukdomar. Via bolagets produkter behandlas personer som lider av flertalet allvarliga hälsotillstånd, inkluderat multipel skleros (MS) samt spinal muskulär atrofi (SMA). En stor del av verksamheten består av forskning och utveckling av nya läkemedel för behandling av flertalet neurologiska sjukdomar. Biogen grundades år 1978 och har huvudkontor i Cambridge, Massachusetts.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2026-03-31 12:59:00 Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology 179,15 USD | -4,45%

2026-03-30 13:30:00 FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy 187,50 USD | +1,47%

2026-03-28 20:00:00 Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

2026-03-20 17:05:00 Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026 181,84 USD | -0,81%

2026-03-19 12:30:00 Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting 183,32 USD | +0,66%

2026-03-11 13:00:00 Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy 190,06 USD | +0,19%

2026-03-05 13:30:00 Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences 187,20 USD | -0,96%

2026-03-04 23:05:00 The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome 187,20 USD | -0,96%

2026-02-11 23:00:00 Biogen Announces Board Chair Transition 195,72 USD | +2,71%

2026-02-09 03:00:00 Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China 192,45 USD | -3,38%

2026-02-04 13:30:00 Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy 180,50 USD | +1,48%

2026-01-28 13:30:00 Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options 171,95 USD | -1,26%

2026-01-26 00:30:00 FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review 172,68 USD | +1,29%

2026-01-12 17:05:00 Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy 184,14 USD | -2,04%

2026-01-06 02:00:00 Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China 180,39 USD | +3,51%

2025-12-22 17:20:00 The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS 175,36 USD | +0,64%

2025-12-09 00:30:00 “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List 178,07 USD | -1,24%

2025-12-05 15:00:00 Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting 182,66 USD | +0,92%

2025-12-04 00:10:00 Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 180,99 USD | -0,30%

2025-12-02 22:40:00 New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF 181,53 USD | +1,66%

2025-12-01 13:30:00 Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting 177,44 USD | -2,59%

2025-11-28 01:30:00 Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan 182,16 USD | +0,58%

2025-11-25 13:30:00 Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status 182,07 USD | +3,29%

2025-11-24 13:30:00 Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions 176,28 USD | +0,66%

2025-11-20 13:30:00 Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer’s Disease Conference 169,32 USD | +1,49%

2025-11-17 13:30:00 Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments 165,66 USD | -0,97%

2025-11-17 12:00:00 High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy 165,66 USD | -0,97%

2025-11-14 22:05:00 Biogen Completes Acquisition of Alcyone Therapeutics

2025-11-14 00:30:00 “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom 167,28 USD | +0,80%

2025-11-03 13:30:00 Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025 150,16 USD | -2,83%

2025-10-27 00:30:00 Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease 149,73 USD | -0,03%

2025-10-24 13:30:44 Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio 149,78 USD | +0,64%

2025-10-22 13:30:00 Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025 147,82 USD | +0,93%

2025-10-14 01:30:00 LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025” 146,00 USD | +0,34%

2025-10-09 22:30:00 Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome 145,51 USD | -2,39%

2025-10-06 22:30:00 Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease 154,16 USD | +0,42%

2025-09-29 01:30:00 “LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in China

2025-09-24 13:30:00 LEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Australia 137,00 USD | -1,83%

2025-09-23 22:30:00 Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen 137,00 USD | -1,83%

2025-09-18 13:40:01 Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates 143,95 USD | -1,49%

2025-09-17 22:30:05 Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe 143,95 USD | -1,49%

2025-09-03 01:30:33 Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status 138,00 USD | +1,00%

2025-09-02 13:00:00 Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome 138,00 USD | +1,00%

2025-08-29 23:00:00 FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

2025-08-25 13:00:00 Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress

2025-08-25 09:00:00 Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)

2025-08-11 13:00:00 Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome 130,69 USD | +0,55%

2025-07-30 17:00:00 Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 128,95 USD | +0,03%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Biogen Inc.

Kalender

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden